Cargando…

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients

Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamroz-Wiśniewska, Anna, Zajdel, Radosław, Słowik, Agnieszka, Marona, Monika, Wnuk, Marcin, Adamczyk-Sowa, Monika, Adamczyk, Bożena, Lasek-Bal, Anetta, Puz, Przemysław, Stęposz, Arkadiusz, Krzystanek, Ewa, Patalong-Ogiewa, Maja, Pokryszko-Dragan, Anna, Budrewicz, Sławomir, Koziarska, Dorota, Karbicka, Anna, Wawrzyniak, Sławomir, Fryze, Waldemar, Furtak-Niczyporuk, Marzena, Rejdak, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122749/
https://www.ncbi.nlm.nih.gov/pubmed/33922368
http://dx.doi.org/10.3390/jcm10091830
_version_ 1783692703657099264
author Jamroz-Wiśniewska, Anna
Zajdel, Radosław
Słowik, Agnieszka
Marona, Monika
Wnuk, Marcin
Adamczyk-Sowa, Monika
Adamczyk, Bożena
Lasek-Bal, Anetta
Puz, Przemysław
Stęposz, Arkadiusz
Krzystanek, Ewa
Patalong-Ogiewa, Maja
Pokryszko-Dragan, Anna
Budrewicz, Sławomir
Koziarska, Dorota
Karbicka, Anna
Wawrzyniak, Sławomir
Fryze, Waldemar
Furtak-Niczyporuk, Marzena
Rejdak, Konrad
author_facet Jamroz-Wiśniewska, Anna
Zajdel, Radosław
Słowik, Agnieszka
Marona, Monika
Wnuk, Marcin
Adamczyk-Sowa, Monika
Adamczyk, Bożena
Lasek-Bal, Anetta
Puz, Przemysław
Stęposz, Arkadiusz
Krzystanek, Ewa
Patalong-Ogiewa, Maja
Pokryszko-Dragan, Anna
Budrewicz, Sławomir
Koziarska, Dorota
Karbicka, Anna
Wawrzyniak, Sławomir
Fryze, Waldemar
Furtak-Niczyporuk, Marzena
Rejdak, Konrad
author_sort Jamroz-Wiśniewska, Anna
collection PubMed
description Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal responders to treatment. The aim of our study was to identify factors that would predict poor response to treatment with natalizumab and fingolimod. Methods: In the multicenter prospective trial, 336 subjects were enrolled, initiating therapy with natalizumab (n = 135) or fingolimod (n = 201). Data on relapse rate, the expanded disability status scale, and MRI results were collected, and MRS was estimated. Results: NEDA-3 after the first year of therapy was 73.9% for natalizumab and 54.8% for fingolimod (p < 0.0001). Patients with MRS = 0 in the last year on platform therapy had the best NEDA-3 (71%) and patients with MRS = 3 had the worst NEDA-3 (41%) in the first year of treatment with the second-line therapy. Conclusion: We conclude that switching to the second-line therapy should occur earlier to enable better results for patients treated with natalizumab or fingolimod. The outcome on both drugs is better with better neurological conditions and lower MRS of the patient on the platform therapy.
format Online
Article
Text
id pubmed-8122749
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81227492021-05-16 Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients Jamroz-Wiśniewska, Anna Zajdel, Radosław Słowik, Agnieszka Marona, Monika Wnuk, Marcin Adamczyk-Sowa, Monika Adamczyk, Bożena Lasek-Bal, Anetta Puz, Przemysław Stęposz, Arkadiusz Krzystanek, Ewa Patalong-Ogiewa, Maja Pokryszko-Dragan, Anna Budrewicz, Sławomir Koziarska, Dorota Karbicka, Anna Wawrzyniak, Sławomir Fryze, Waldemar Furtak-Niczyporuk, Marzena Rejdak, Konrad J Clin Med Brief Report Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal responders to treatment. The aim of our study was to identify factors that would predict poor response to treatment with natalizumab and fingolimod. Methods: In the multicenter prospective trial, 336 subjects were enrolled, initiating therapy with natalizumab (n = 135) or fingolimod (n = 201). Data on relapse rate, the expanded disability status scale, and MRI results were collected, and MRS was estimated. Results: NEDA-3 after the first year of therapy was 73.9% for natalizumab and 54.8% for fingolimod (p < 0.0001). Patients with MRS = 0 in the last year on platform therapy had the best NEDA-3 (71%) and patients with MRS = 3 had the worst NEDA-3 (41%) in the first year of treatment with the second-line therapy. Conclusion: We conclude that switching to the second-line therapy should occur earlier to enable better results for patients treated with natalizumab or fingolimod. The outcome on both drugs is better with better neurological conditions and lower MRS of the patient on the platform therapy. MDPI 2021-04-22 /pmc/articles/PMC8122749/ /pubmed/33922368 http://dx.doi.org/10.3390/jcm10091830 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Jamroz-Wiśniewska, Anna
Zajdel, Radosław
Słowik, Agnieszka
Marona, Monika
Wnuk, Marcin
Adamczyk-Sowa, Monika
Adamczyk, Bożena
Lasek-Bal, Anetta
Puz, Przemysław
Stęposz, Arkadiusz
Krzystanek, Ewa
Patalong-Ogiewa, Maja
Pokryszko-Dragan, Anna
Budrewicz, Sławomir
Koziarska, Dorota
Karbicka, Anna
Wawrzyniak, Sławomir
Fryze, Waldemar
Furtak-Niczyporuk, Marzena
Rejdak, Konrad
Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
title Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
title_full Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
title_fullStr Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
title_full_unstemmed Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
title_short Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
title_sort modified rio score with platform therapy predicts treatment success with fingolimod and natalizumab in relapsing-remitting multiple sclerosis patients
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122749/
https://www.ncbi.nlm.nih.gov/pubmed/33922368
http://dx.doi.org/10.3390/jcm10091830
work_keys_str_mv AT jamrozwisniewskaanna modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT zajdelradosław modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT słowikagnieszka modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT maronamonika modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT wnukmarcin modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT adamczyksowamonika modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT adamczykbozena modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT lasekbalanetta modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT puzprzemysław modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT steposzarkadiusz modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT krzystanekewa modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT patalongogiewamaja modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT pokryszkodragananna modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT budrewiczsławomir modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT koziarskadorota modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT karbickaanna modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT wawrzyniaksławomir modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT fryzewaldemar modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT furtakniczyporukmarzena modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients
AT rejdakkonrad modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients